Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Brief Summary: This study is being conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational drug, PF-04447943, in subjects with stable sickle cell disease with and without co-administration with hydroxyurea. This study will also aid in selecting the doses for future studies and evaluation of substances in the blood which may help access the effectiveness of the drug.


Options:
A: Arm Label: Placebo Pills and Placebo Liquid; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Pills and Placebo Liquid | Arm Label: Hydroxyurea Pills and Placebo Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Pidolate | Arm Label: Hydroxyurea Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Drug: Magnesium Pidolate | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Hydroxyurea Pills and Placebo Liquid | Intervention Type: DRUG; Name: Magnesium Pidolate; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Placebo Pills and Magnesium Pidolate Liquid | Intervention Type: OTHER; Name: Placebo Pills and Placebo Liquid; Assigned to Arm(s): Placebo Pills and Placebo Liquid
B: Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: cohort 1 PF-04447943; Type: EXPERIMENTAL; Interventions: Drug: PDE9i | Arm Label: cohort 2 PF-04447943; Type: EXPERIMENTAL; Interventions: Drug: PDE9i | Arm Label: placebo comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for PDE9i | Arm Label: optional cohort of PF-04447943; Type: EXPERIMENTAL; Interventions: Drug: PDE9i | Intervention Type: DRUG; Name: PDE9i; Assigned to Arm(s): cohort 1 PF-04447943, optional cohort of PF-04447943 | Intervention Type: DRUG; Name: PDE9i; Assigned to Arm(s): cohort 2 PF-04447943, optional cohort of PF-04447943 | Intervention Type: DRUG; Name: placebo for PDE9i; Assigned to Arm(s): placebo comparator | Intervention Type: DRUG; Name: PDE9i; Assigned to Arm(s): optional cohort of PF-04447943
D: Arm Label: Montelukast added to Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Montelukast added to Hydroxyurea | Arm Label: Placebo added to Hydroxyurea; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo added to Hydroxyurea | Intervention Type: DRUG; Name: Montelukast added to Hydroxyurea; Assigned to Arm(s): Montelukast added to Hydroxyurea | Intervention Type: DRUG; Name: Placebo added to Hydroxyurea; Assigned to Arm(s): Placebo added to Hydroxyurea

Answer: C